By Nick Paul Taylor
Gilead’s $4.9 billion bet on Forty Seven has run into a delay. Weeks after Takeda’s rival drug flunked a pivotal trial, Gilead has pushed back the release of data from a phase 1b study designed to support accelerated approval.
read more
By Rebecca Torrence
Aetna is launching a new network to cover gene therapies for inherited retinal disease and spinal muscular atrophy. The insurer expects gene therapies to add $45 billion to healthcare costs between 2020 and 2024 if the FDA approves all other therapies currently in the pipeline.
read more
By Kevin Dunleavy
Veklury was thought to be in decline as a treatment for hospitalized COVID-19 patients. But to the surprise of even Gilead, the antiviral staged a comeback in the third quarter, posting $1.9 billion in sales and allowing the company to bump up its projection for annual revenues.
read more
By Kyle LaHucik
Researchers at University of Queensland collaborated with Vaxxas to develop a COVID-19 patch that warded off the virus in mice. They hope to raise funding to bring the patch into clinical testing but are facing competition from existing vaccines and other patch developers.
read more
By Conor Hale
Following the launch of its benchtop DNA printer earlier this year, DNA Script is preparing to take its platform to the masses. Using four specially prepared genetic “inks”—G, A, T and C—the strings of genetic code are assembled letter by letter, before being delivered in a purified, ready-to-use format.
read more
By Robert King
The Department of Health and Human Services proposed getting rid of a controversial Trump-era rule that would spark a massive agency review of all existing regulations, arguing that the previous administration vastly underestimated the cost of compliance.
read more
By Nick Paul Taylor
Daiichi Sankyo’s antibody-drug conjugate team has hit a rare bump in the road, dumping a gastrointestinal stromal tumor candidate after seeing “no clear responses” in a phase 1 trial.
read more
By Dave Muoio
Young AI companies supported by the joint venture will have access to the health system's clinical data and experts as well as the venture firm's commercialization experience.
read more
By Emmy Lucas
The NIH will invest $74.5 million through a new program to establish data science research centers and training across Africa.
read more
By Angus Liu
AbbVie’s antipsychotic Vraylar could get a major boost from a potential expansion into depression. But like some other late-stage contenders, the drug’s clinical results fell short of a home run.
read more
By Conor Hale
The neurostimulation startup Magnus Medical is raising the curtain with $25 million in hand and an FDA breakthrough designation for its personalized treatment for severe cases of depression.
read more
By Ben Adams
Little U.S.-China startup Signet Therapeutics has bagged a second seed round worth around $10 million as plots a path to the clinic.
read more
